Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics insider transaction: Chief Executive Officer and director Richard Nolan Townsend reported a sale of 2,735 shares of Lexeo Therapeutics common stock on 08/18/2025 at a price of $4.668 per share. The filing states the sale was executed to cover tax obligations related to the release of restricted stock units (RSUs).
After the reported transaction, Townsend beneficially owns 220,058 shares, which the filing notes include 131,092 RSUs. The report was filed as a Form 4 disclosing an individual insider sale described as a tax-withholding disposition of equity awards.
Insider sale to cover taxes at Lexeo Therapeutics (LXEO) Reporting person Tai Sandi, Chief Development Officer, reported a sale of 382 shares of common stock on 08/18/2025 at $4.668 per share. The filing states the sale was a "sale to cover" related to the release of restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 58,860 shares, which the filer notes include 49,138 RSUs. The Form 4 was signed by an attorney-in-fact on 08/20/2025. No derivative transactions or other securities changes are reported in this filing.
Lexeo Therapeutics (LXEO) filed a Form 144 reporting a proposed sale of 2,848 common shares held by an insider following restricted stock vesting. The shares have an aggregate market value of $13,295.03 and represent a small fraction of the company's outstanding common stock of 54,001,214 shares. The filing lists Fidelity Brokerage Services LLC as the broker and an approximate sale date of 08/18/2025. The acquisition source is shown as restricted stock vesting on 08/15/2025 with payment characterized as compensation. No other sales in the past three months were reported.
Form 144 notice filed for Lexeo Therapeutics, Inc. (LXEO) reporting a proposed sale of 608 shares of common stock (approximate aggregate market value $2,838.27) from restricted stock that vested on 08/15/2025. The filing shows the shares are expected to be sold on 08/18/2025 through Fidelity Brokerage Services LLC on NASDAQ. The securities were acquired by vesting as compensation from the issuer on 08/15/2025, and there are 54,001,214 shares outstanding per the filing. The filer certifies they are not aware of undisclosed material adverse information.
Lexeo Therapeutics (LXEO) filing Form 144 to notify a proposed sale of 1,115 common shares through Fidelity Brokerage Services on 08/18/2025. The shares were acquired on 08/15/2025 upon restricted stock vesting from the issuer and the consideration is listed as compensation. The filing reports an aggregate market value of $5,205.04 for the shares and shows 54,001,214 shares outstanding, indicating the sale represents a very small fraction of the outstanding common stock. The filer certifies under the form that they are not aware of undisclosed material adverse information about the issuer.
Lexeo Therapeutics (LXEO) reported a Form 144 notice for the proposed sale of 382 common shares, with an aggregate market value of $1,783.25, to be sold on 08/18/2025 on NASDAQ. The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and were paid as compensation. The filing shows 54,001,214 shares outstanding and notes no securities sold by the filer in the past three months. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Form 144 filed for Lexeo Therapeutics, Inc. (LXEO) reports a proposed sale of 542 common shares, with an aggregate market value of $2,530.16, to be sold on 08/18/2025 on NASDAQ through Fidelity Brokerage Services LLC.
The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and payment/settlement is recorded as 08/15/2025. The filing shows 54,001,214 shares outstanding for the class and indicates no other sales in the past three months.
Citadel-linked entities disclose a substantial passive stake in Lexeo Therapeutics (LXEO). Collectively, Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC report beneficial ownership of 5,325,269 shares, representing 9.6% of outstanding shares on a fully calculated basis of 55,718,516 shares (including 1,717,302 shares issuable upon warrant conversion). Citadel Securities entities separately report 8,843 shares. Kenneth Griffin is reported to beneficially own 5,334,112 shares (also 9.6%). The filing states the positions were not acquired to change or influence control and identifies the reporting persons, organization structure and shared voting/dispositive powers.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 3,228,161 shares of Lexeo Therapeutics, Inc. (ticker LXEO), representing 6.0% of the outstanding common stock. The percentage is calculated using an aggregate share count of 53,987,117 shares, reflecting 33,196,997 shares reported as of May 9, 2025, plus 20,790,120 shares issued in a May 27, 2025 private placement. Vestal Point acts as investment manager to a fund and a managed account that hold the shares; Mr. Wilder is the investment manager’s CIO and managing partner and signed the filing. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control.
This Schedule 13G/A reports the beneficial ownership positions of multiple Frazier Life Sciences entities in Lexeo Therapeutics, Inc. common stock and clarifies prior attributions. Frazier Life Sciences Public Fund, L.P. directly holds 3,073,467 shares and related entities hold additional positions including 624,804, 87,424, 232,784 and 406,246 shares across several affiliated funds, with individual percentages reported as high as 5.7% and others at 1.2%, 0.2%, 0.4% and 0.8% respectively.
The filing states these reported share amounts exclude certain warrants and discloses warrant ceilings: FLSPF holds warrants to purchase 2,647,440 shares; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; and FLS XII 507,809, each subject to a ~9.99% beneficial-ownership exercise limit. The statement explains shared voting and dispositive power structures through general partners and investment committees and corrects any prior over-attribution to individual committee members. The percentage calculations rely on the issuer's reported outstanding shares and shares sold in a public offering as set forth in the filing.